ArriVent BioPharma, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Zhengbin Yao Ph.D.
- Employees
- 77
- Headquarters
- Newtown Square, PA, United States
- Website
- arrivent.com